In United States v. Melgen, No. 18-10991 (July 31,
2020) (Grant, Martin, Lagoa), the Court affirmed the defendant’s Medicare
fraud convictions and sentence.
First, the Court rejected the defendant’s argument that the
district court erred by giving the pattern instruction on materiality. The Court rejected the defendant’s reliance
on a Supreme Court case addressing the False Claims Act.
Second, the Court found no error in the introduction of
summary charts comparing the defendant’s billing to peer physicians. The charts were admissible under Rule 1006. The Confrontation Clause did not permit the
defendant to cross examine decision-makers about the criteria used to make the
charts (namely, the prosecutors). And no
expert witness was required to admit the charts.
Third, the Court rejected five errors about his trial. First, the district court did not err in
admitting evidence of multi-dosing, since it was probative of his profit
motive. Second, no mistrial was required
due to a witness’ false testimony because
the court immediately issued a thorough curative instruction. Third, the court’s refusal to instruct the
jury that a sample of patient files was not statistically random did not require
a mistrial, because the court instructed the jury to disregard any statements concerning
statistical confidence. Fourth, the
district court did not commit plain error by giving the jury unredacted copies
of the indictment because the court told the jury that it was not evidence of
guilt and there was no potential prejudice.
Finally, no mistrial was required by contact between the government and
defense witnesses after the court conducted a hearing and determined that the
contact had not been prejudicial or altered any testimony.
Fourth, the Court concluded that sufficient evidence
supported the convictions, as the defendant’s argument went to the weight of
the evidence.
Fifth, the Court upheld the denial of a motion for new trial
based on a Brady violation, which was based on medical testimony by a
government witness at sentencing. This
testimony was neither new nor likely to change the outcome of the trial. And it was merely impeachment evidence, and so
not the basis of a new trial under Rule 33.
Finally, as to the sentence, the Court found no clear error
in the loss amount, as the government presented enough evidence that the sample
patient group was representative of the defendant’s patient population. And his below-guideline sentence was not
substantively unreasonable.